Acceleron Pharma, Inc.: Series D $30.4M

Posted in I - Series D, Q - 4Q11, R - NORTH EAST, X - Anemia, X - Muscular Dystrophy, X - Oncology, X - Osteoporosis, XX - MA

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Feb

2010

PTC Therapeutics, Inc.: Series E $50M

Posted in I - Series E, Q - 4Q09, R - NORTH EAST, X - CF, X - Hemophilia, X - Muscular Dystrophy, XX - NJ

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2009

Prosensa, BV: Series B $25.0M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Muscular Dystrophy, X - RNAi

Prosena (The Netherlands) developer of RNA-based splice modulating therapeutics closed a $25M Series B financing. Participants include GIMV, AGF Management, Abingworth Management, Life Sciences Partnersand MedSciences Capital.

Feb

2007

Prosensa Holding BV: Series A $18M

Posted in I - Series A, R - INTERNATIONAL, X - Muscular Dystrophy

Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.

to top of page...